Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 75,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was bought at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the purchase, the insider now owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Radius Health Inc (NASDAQ RDUS) traded up $1.26 during midday trading on Monday, hitting $36.42. 564,597 shares of the stock were exchanged, compared to its average volume of 883,262. The firm has a market capitalization of $1,620.00, a PE ratio of -6.71 and a beta of 1.21. Radius Health Inc has a 52-week low of $24.66 and a 52-week high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.
RDUS has been the subject of several research analyst reports. Jefferies Group decreased their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup initiated coverage on shares of Radius Health in a research note on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, BidaskClub downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average target price of $51.78.
ILLEGAL ACTIVITY WARNING: “Growth N. V. Biotech Acquires 75,000 Shares of Radius Health Inc (RDUS) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/growth-n-v-biotech-acquires-75000-shares-of-radius-health-inc-rdus-stock.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.